3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
193
Lung Neoplasms
80
Pancreatic Neoplasms
47
Neoplasms
31
Non-Squamous Non-Small Cell Lung Cancer
19
Head and Neck Neoplasms
19
Glioblastoma
19
Adenocarcinoma of Lung
19
Squamous Cell Carcinoma of Head and Neck
18
Neoplasm Metastasis
17
Gliosarcoma
17
Brain Neoplasms
17
Breast Neoplasms
16
Rectal Neoplasms
13
Colorectal Neoplasms
13
Colonic Neoplasms
13
Adenocarcinoma, Bronchiolo-Alveolar
13
Carcinoma, Hepatocellular
11
Carcinoma, Renal Cell
10
Glioma
8
Astrocytoma
8
Salivary Gland Neoplasms
7
Gallbladder Neoplasms
7
Esophageal Neoplasms
7
Carcinoma, Ovarian Epithelial
7
Prostatic Neoplasms
6
Ovarian Neoplasms
6
Oligodendroglioma
6
Fallopian Tube Neoplasms
6
Carcinoma, Squamous Cell
6
Interventions
dacetuzumab
6
blinatumomab
6
Rituximab
4
Epoetin Alfa
4
Lenalidomide
3
Dexamethasone
3
Darbepoetin alfa
3
Cyclophosphamide
3
Bortezomib
3
Therapeutics
2
Everolimus
2
Early Intervention, Educational
2
Alemtuzumab
2
venetoclax
1
vandetanib
1
tirbanibulin
1
tetulomab tetraxetan lu-177
1
ponatinib
1
plerixafor
1
pembrolizumab
1
pegaspargase
1
isatuximab
1
imetelstat
1
ibrutinib
1
fludarabine
1
ficlatuzumab
1
ferrous sulfate
1
ferric gluconate
1
ferric carboxymaltose
1
durvalumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Lymphoproliferative Disorders
×
Erlotinib Hydrochloride
×
Clear all
NCT00725634
2014-01-27
P05538
AVEO Pharmaceuticals, Inc.
Phase 1
Completed
41 enrolled